In the second part, the discussion turns to emerging DED therapies that target tear function and ocular surface homeostasis.
Formosa and Rxilient have an exclusive licensing agreement for APP13007 commercialization, including regulatory and sales ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback